Company News

Current

June 17, 2010 - SmartCells Completes Series D Preferred Stock Financing
SmartCells, Inc. completed its $4.1 million Series D financing on June 16, 2010. The size of the round was increased to accommodate additional subscription requests. Purchasers include members of the Boston Harbor Angels, Angel Healthcare Investors, Beacon Street Angels, Cherrystone Angels and Common Angels. Dr. Todd C. Zion, SmartCells' co-founder, President and CEO said, “I am gratified that so many of our Series A, B and C investors participated in this round and I welcome those that invested for the first time. We plan to use the proceeds to initiate the first human trial of SmartInsulin, our glucose-responsive insulin formulation.”

September 25, 2009 – SmartCells, Inc. Awarded Phase II SBIR by NIH/NIDDK
SmartCells, Inc. received notice that it has been awarded $1,578,278 in first year funding for a Phase II SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The grant was awarded to support IND-enabling toxicology and safety pharmacology studies of SmartInsulin, the company’s glucose-regulated insulin formulation. The second year of the Phase II grant allocates $337,365 in additional funding.

August 1, 2009 – SmartCells, Inc. Receives Additional Phase II SBIR Funds from NIH/NIDDK
SmartCells, Inc. received notice that it has been awarded $850,859 in second year funding for a Phase II SBIR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). The funds will support manufacturing development for the company’s glucose-regulated insulin formulation. Support for the second year was provided on the basis of achieving goals during the first year of the grant, which provided $1,546,698 in funding.

July 28, 2009 - SmartCells Completes Convertible Debt Financing
SmartCells, Inc. completed the sale of $1.15 million in Convertible Notes on July 28, 2009, all to current shareholders. The size of the offering was increased to accommodate purchase requests. Purchasers include members of the Boston Harbor Angels, Angel Healthcare Investors, Beacon Street Angels, Cherrystone Angels and Common Angels. Dr. Todd C. Zion, SmartCells' co-founder, President and CEO said, “I am gratified at the continuing support from our Series A, B and C investors who belong to the Boston area’s leading angel investing groups. The proceeds, together with grant awards, will help support the safety testing and manufacturing work needed to move SmartInsulin, our glucose-responsive insulin formulation, into the clinic”.

May 12th, 2009 – SmartCells, Inc. and Massachusetts Institute of Technology (MIT) Obtain Initial U.S. Patent from Founder’s Research
SmartCells, Inc. and MIT received notice from the USPTO that U.S. Patent 7,531,191 titled “Stimuli-Responsive Nanoparticles for Controlled Drug Delivery” was awarded to Dr. Todd Zion, founder and CEO of SmartCells, Inc. and certain co-inventors. The original technology, which led to the founding of SmartCells in 2003, was developed by Dr Zion while a graduate student at MIT and provides the initial basis for the company’s SmartInsulin drug development programs. The company has executed an exclusive license agreement with MIT to obtain rights to all of the intellectual property originating from Dr Zion’s work and expects that additional patents based on Dr Zion’s research will be forthcoming.